We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Pavmed (MM) | NASDAQ:PAVMU | NASDAQ | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 14.53 | 10.44 | 30.00 | 0 | 01:00:00 |
PAVmed Inc. (Nasdaq:PAVM), a highly differentiated, multi-product medical device company, today announced that the Company will host a conference call on August 17, 2016 at 4:30 p.m. Eastern time during which PAVmed’s Chairman and CEO, Dr. Lishan Aklog, will provide a business update and discuss near term milestones and growth strategy.
To access the conference call, U.S.-based listeners should dial (844) 666-7591 and international listeners should dial (443) 961-0431. All listeners should provide the following passcode: 65791790. Individuals interested in listening to the live conference call via the Internet may do so by logging on to the Company’s website at www.pavm.com.
Following the conclusion of the conference call, a replay will be available through August 24, 2016 and can be accessed by dialing (855) 859-2056 from within the U.S. or (404) 537-3406 from outside the U.S. All listeners should provide passcode 9950. The webcast will be available for 90 days.
About PAVmed
PAVmed Inc. (Nasdaq:PAVM) is a highly differentiated, multi-product medical device company employing a unique business model designed to advance products from concept to commercialization much more rapidly and with significantly less capital than the typical medical device company. This proprietary model enables PAVmed to pursue an expanding multi-product pipeline strategy with a view to enhancing and accelerating value creation. PAVmed’s diversified pipeline of products address unmet clinical needs, have attractive regulatory pathways and market opportunities and encompass a broad spectrum of clinical areas including carpal tunnel syndrome (CarpX™), medical infusions (NextFlo™ and NextCath™), interventional radiology (PortIO™ and NextCath), tissue ablation and cardiovascular intervention (Caldus™). The Company intends to further expand its pipeline through engagements with clinician innovators and leading academic medical centers. For further information, please visit www.pavm.com
View source version on businesswire.com: http://www.businesswire.com/news/home/20160812005603/en/
For PAVmed Inc.InvestorsLHAKim Sutton Golodetz, 212-838-3777kgolodetz@lhai.comOrMediaErich Sandoval, 917-497-2867esandoval@lazarpartners.com
1 Year Pavmed (MM) Chart |
1 Month Pavmed (MM) Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions